| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
14,627 |
11,546 |
$1.47M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
26,827 |
22,877 |
$950K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
23,820 |
19,440 |
$940K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,060 |
10,273 |
$283K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
1,957 |
1,730 |
$171K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,129 |
2,432 |
$158K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
1,621 |
1,514 |
$97K |
| 99429 |
|
434 |
421 |
$29K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
388 |
346 |
$27K |
| 99441 |
|
878 |
792 |
$19K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,405 |
946 |
$14K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,369 |
763 |
$14K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,425 |
747 |
$14K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,001 |
888 |
$11K |
| 99215 |
Prolong outpt/office vis |
178 |
156 |
$10K |
| 99497 |
|
239 |
202 |
$7K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
108 |
104 |
$7K |
| 82962 |
|
4,237 |
3,365 |
$7K |
| 90674 |
|
406 |
331 |
$6K |
| 99406 |
|
1,015 |
899 |
$6K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
285 |
225 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
165 |
139 |
$4K |
| 90756 |
|
308 |
275 |
$3K |
| 84443 |
Thyroid stimulating hormone (TSH) |
345 |
282 |
$3K |
| 84481 |
|
338 |
278 |
$3K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
45 |
40 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
361 |
268 |
$3K |
| 90686 |
|
264 |
243 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
41 |
39 |
$3K |
| 82607 |
|
255 |
211 |
$2K |
| 82746 |
|
252 |
209 |
$2K |
| 84439 |
|
338 |
278 |
$2K |
| 99442 |
|
45 |
41 |
$2K |
| 82728 |
|
189 |
154 |
$1K |
| 82948 |
|
535 |
490 |
$848.77 |
| 86769 |
|
19 |
17 |
$629.40 |
| 84403 |
|
40 |
32 |
$607.27 |
| 90658 |
|
35 |
35 |
$514.26 |
| 84153 |
|
41 |
34 |
$424.61 |
| 90688 |
|
25 |
25 |
$421.90 |
| 82043 |
|
109 |
97 |
$350.65 |
| 96160 |
|
94 |
83 |
$177.66 |
| 36415 |
Collection of venous blood by venipuncture |
332 |
270 |
$173.34 |
| 86803 |
|
27 |
16 |
$134.17 |
| 86705 |
|
27 |
16 |
$110.67 |
| 86709 |
|
27 |
16 |
$105.86 |
| 1159F |
|
31,154 |
26,391 |
$32.47 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
16,469 |
14,076 |
$15.60 |
| G0008 |
Administration of influenza virus vaccine |
58 |
47 |
$13.66 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
3,614 |
3,093 |
$10.51 |
| 84436 |
|
113 |
88 |
$6.87 |
| 84479 |
|
111 |
87 |
$6.47 |
| 1160F |
|
34,605 |
29,330 |
$3.28 |
| 3077F |
|
2,590 |
2,237 |
$0.01 |
| 3078F |
|
3,202 |
2,787 |
$0.01 |
| 3080F |
|
2,712 |
2,363 |
$0.01 |
| 1125F |
|
6,485 |
5,363 |
$0.01 |
| 3074F |
|
3,677 |
3,208 |
$0.01 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
4,485 |
3,780 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
206 |
191 |
$0.00 |
| 3085F |
|
13 |
12 |
$0.00 |
| 3288F |
|
17 |
13 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
17,936 |
15,149 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
54 |
39 |
$0.00 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
2,860 |
2,510 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,241 |
1,142 |
$0.00 |
| 3079F |
|
1,943 |
1,735 |
$0.00 |
| 3075F |
|
1,516 |
1,359 |
$0.00 |
| 1101F |
|
18 |
12 |
$0.00 |
| 1170F |
|
20 |
16 |
$0.00 |
| 1034F |
|
14 |
13 |
$0.00 |
| 1111F |
|
14 |
14 |
$0.00 |